ID30064A - Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion - Google Patents

Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion

Info

Publication number
ID30064A
ID30064A IDW00200101331A ID20011331A ID30064A ID 30064 A ID30064 A ID 30064A ID W00200101331 A IDW00200101331 A ID W00200101331A ID 20011331 A ID20011331 A ID 20011331A ID 30064 A ID30064 A ID 30064A
Authority
ID
Indonesia
Prior art keywords
crystal
methyl
tiazolidinedion
fluorobenzil
oksi
Prior art date
Application number
IDW00200101331A
Other languages
English (en)
Inventor
Takayuki Oe
Hiroaki Ueno
Akira Maruyama
Katsuhiko Masuda
Original Assignee
Mitsibishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsibishi Chemical Corp filed Critical Mitsibishi Chemical Corp
Publication of ID30064A publication Critical patent/ID30064A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Photoreceptors In Electrophotography (AREA)
IDW00200101331A 1998-11-20 1999-11-19 Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion ID30064A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33054698 1998-11-20

Publications (1)

Publication Number Publication Date
ID30064A true ID30064A (id) 2001-11-01

Family

ID=18233859

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101331A ID30064A (id) 1998-11-20 1999-11-19 Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion

Country Status (23)

Country Link
US (3) US6541493B1 (id)
EP (1) EP1131310B1 (id)
JP (1) JP3784001B2 (id)
KR (1) KR100652326B1 (id)
CN (1) CN1326449A (id)
AT (1) ATE315552T1 (id)
AU (1) AU1185100A (id)
BR (1) BR9916795A (id)
CA (1) CA2351727C (id)
CZ (1) CZ20011763A3 (id)
DE (1) DE69929476T2 (id)
ES (1) ES2257104T3 (id)
HU (1) HUP0104139A3 (id)
ID (1) ID30064A (id)
IL (1) IL143177A0 (id)
NO (1) NO20012444L (id)
NZ (1) NZ512429A (id)
PL (1) PL348502A1 (id)
PT (1) PT1131310E (id)
TR (4) TR200202110T2 (id)
TW (2) TWI250156B (id)
WO (1) WO2000031055A1 (id)
ZA (1) ZA200104081B (id)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE315552T1 (de) * 1998-11-20 2006-02-15 Mitsubishi Chem Corp 5-((6-(2-fluorbenzyl)oxy-2-naphtyl)methyl)- thiazolid in-2,4-dion kristallen
CN1423639A (zh) * 1999-11-19 2003-06-11 奥索-麦克尼尔药品公司 5－[[6－[(2－氟苯基)甲氧基]－2－萘基]甲基]－2,4－噻唑烷二酮的多种固态形式
ATE423559T1 (de) * 2001-04-04 2009-03-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
WO2007049050A2 (en) * 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
KR20130087048A (ko) * 2008-02-04 2013-08-05 화이자 리미티드 염증성 질환을 치료하기 위한 [1,2,4]트라이아졸로[4,3-ａ]피리딘 유도체의 다형체 형태

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JP4023697B2 (ja) 1996-11-14 2007-12-19 三菱化学株式会社 ナフタレン誘導体の製造方法
ATE315552T1 (de) * 1998-11-20 2006-02-15 Mitsubishi Chem Corp 5-((6-(2-fluorbenzyl)oxy-2-naphtyl)methyl)- thiazolid in-2,4-dion kristallen

Also Published As

Publication number Publication date
BR9916795A (pt) 2002-04-09
PL348502A1 (en) 2002-05-20
DE69929476T2 (de) 2006-09-14
PT1131310E (pt) 2006-05-31
ATE315552T1 (de) 2006-02-15
HUP0104139A2 (hu) 2002-03-28
CZ20011763A3 (cs) 2001-10-17
AU1185100A (en) 2000-06-13
EP1131310B1 (en) 2006-01-11
CN1326449A (zh) 2001-12-12
WO2000031055A1 (en) 2000-06-02
KR20010101033A (ko) 2001-11-14
NO20012444D0 (no) 2001-05-18
ES2257104T3 (es) 2006-07-16
IL143177A0 (en) 2002-04-21
TR200202103T2 (tr) 2002-11-21
DE69929476D1 (de) 2006-04-06
HUP0104139A3 (en) 2003-12-29
CA2351727A1 (en) 2000-06-02
US20030158241A1 (en) 2003-08-21
NO20012444L (no) 2001-07-18
EP1131310A1 (en) 2001-09-12
TWI250156B (en) 2006-03-01
KR100652326B1 (ko) 2006-11-29
NZ512429A (en) 2003-11-28
TR200101901T2 (tr) 2002-04-22
TR200202110T2 (tr) 2002-10-21
TR200202109T2 (tr) 2002-11-21
JP3784001B2 (ja) 2006-06-07
JP2002530392A (ja) 2002-09-17
TW200613291A (en) 2006-05-01
TWI272944B (en) 2007-02-11
US6541493B1 (en) 2003-04-01
ZA200104081B (en) 2002-05-20
US20060149075A1 (en) 2006-07-06
CA2351727C (en) 2008-09-23

Similar Documents

Publication Publication Date Title
HUP0203841A3 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
KR970704687A (ko) 무스카린성 수용체에서 알로스테릭 효과기로서 유용한 헤테로고리 화합물(heterocyclic compounds, useful as allosteric effectors at muscarinic receptors)
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
WO2000017190A3 (fr) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
AR031069A1 (es) Cristal de un compuesto benzimidazol, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima
IL126674A (en) Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
EA200000656A1 (ru) Замещенное производное тиазолидиндиона, способ его получения и его фармацевтическое применение
CA2130174A1 (en) 4-oxo-2 thioxoimidazolidine derivatives as inhibitors of blood platelet aggregation
NZ237884A (en) N-hydroxy-n-linolanyl (chromanyl or quinolinyl) alkyl urea and amide derivatives, preparation and pharmaceutical compositions thereof
EA200000655A1 (ru) Гидрат соли малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона
ID30064A (id) Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion
EA200101101A1 (ru) Новый фармацевтический препарат
IT1206130B (it) Composti per abbassare i livelli dei lipidi.
IT1303793B1 (it) "composizione farmaceutica comprendente un composto organico donatoredi ossido nitrico (no)"
EE03090B1 (et) Kinoliin-3-karboksamiidühendite kasutamine kompositsiooni valmistamiseks I tüüpi suhkurtõve raviks
NZ214201A (en) Crystalline polymorph of a benzothiazine dioxide (piroxicam) salt, and pharmaceutical compositions
EP0256507A3 (en) 3-(1h-tetrazol-5-yl)oxanilic acid and salts thereof, method for preparing the same and pharmaceutical compositions containing the compound
CA2319359A1 (en) Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers
IL67564A0 (en) (1,2)-fused 1,4-benzodiazepine compounds,their preparation and pharmaceutical compositions containing them
HUP9803041A3 (en) Thiazole derivatives, process for the preparation thereof, use thereof and pharmaceutical compositions containing them
JPS57206683A (en) Pyrimidone salt, manufacture and medicinal composition containing same
WO2001060344A3 (en) Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections
NO970477D0 (no) Inhibisjon av leukotrien biosyntese med ureaderivater
WO1993018059A3 (en) L-thiazolidine-4-carboxylic acid derivative, processes for the preparation thereof and the use thereof in therapy